Literature DB >> 28522570

Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma.

Yolanda Campos-Martín1, Nerea Martínez2, Azahara Martínez-López3, Laura Cereceda2, Felipe Casado4, Patrocinio Algara5, David Oscier6, Francisco J Menarguez7, Juan F García8, Miguel A Piris9, Manuela Mollejo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28522570      PMCID： PMC5541884          DOI： 10.3324/haematol.2016.161711

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.

Authors:  R Piva; S Deaglio; R Famà; R Buonincontri; I Scarfò; A Bruscaggin; E Mereu; S Serra; V Spina; D Brusa; G Garaffo; S Monti; M Dal Bo; R Marasca; L Arcaini; A Neri; V Gattei; M Paulli; E Tiacci; F Bertoni; S A Pileri; R Foà; G Inghirami; G Gaidano; D Rossi
Journal:  Leukemia       Date:  2014-10-06       Impact factor: 11.528

2.  The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.

Authors:  Luca Arcaini; Davide Rossi; Marco Lucioni; Marta Nicola; Alessio Bruscaggin; Valeria Fiaccadori; Roberta Riboni; Antonio Ramponi; Virginia V Ferretti; Stefania Cresta; Gloria Margiotta Casaluci; Maurizio Bonfichi; Manuel Gotti; Michele Merli; Aldo Maffi; Mariarosa Arra; Marzia Varettoni; Sara Rattotti; Lucia Morello; Maria Luisa Guerrera; Roberta Sciarra; Gianluca Gaidano; Mario Cazzola; Marco Paulli
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

3.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Authors:  A Clipson; M Wang; L de Leval; M Ashton-Key; A Wotherspoon; G Vassiliou; N Bolli; C Grove; S Moody; L Escudero-Ibarz; G Gundem; K Brugger; X Xue; E Mi; A Bench; M Scott; H Liu; G Follows; E F Robles; J A Martinez-Climent; D Oscier; A J Watkins; M-Q Du
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

4.  Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.

Authors:  Marina Parry; Matthew Jj Rose-Zerilli; Viktor Ljungström; Jane Gibson; Jun Wang; Renata Walewska; Helen Parker; Anton Parker; Zadie Davis; Anne Gardiner; Neil McIver-Brown; Christina Kalpadakis; Aliki Xochelli; Achilles Anagnostopoulos; Claudia Fazi; David Gonzalez de Castro; Claire Dearden; Guy Pratt; Richard Rosenquist; Margaret Ashton-Key; Francesco Forconi; Andrew Collins; Paolo Ghia; Estella Matutes; Gerassimos Pangalis; Kostas Stamatopoulos; David Oscier; Jonathan C Strefford
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

5.  DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.

Authors:  Alberto J Arribas; Andrea Rinaldi; Afua A Mensah; Ivo Kwee; Luciano Cascione; Eloy F Robles; Jose A Martinez-Climent; David Oscier; Luca Arcaini; Luca Baldini; Roberto Marasca; Catherine Thieblemont; Josette Briere; Francesco Forconi; Alberto Zamò; Massimiliano Bonifacio; Manuela Mollejo; Fabio Facchetti; Stephan Dirnhofer; Maurilio Ponzoni; Govind Bhagat; Miguel A Piris; Gianluca Gaidano; Emanuele Zucca; Davide Rossi; Francesco Bertoni
Journal:  Blood       Date:  2015-01-22       Impact factor: 22.113

6.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

Review 7.  Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.

Authors:  E Matutes; D Oscier; C Montalban; F Berger; E Callet-Bauchu; A Dogan; P Felman; V Franco; E Iannitto; M Mollejo; T Papadaki; E D Remstein; A Salar; F Solé; K Stamatopoulos; C Thieblemont; A Traverse-Glehen; A Wotherspoon; B Coiffier; M A Piris
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

8.  Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.

Authors:  Mark J Kiel; Thirunavukkarasu Velusamy; Bryan L Betz; Lili Zhao; Helmut G Weigelin; Mark Y Chiang; David R Huebner-Chan; Nathanael G Bailey; David T Yang; Govind Bhagat; Roberto N Miranda; David W Bahler; L Jeffrey Medeiros; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

9.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Authors:  Davide Rossi; Vladimir Trifonov; Marco Fangazio; Alessio Bruscaggin; Silvia Rasi; Valeria Spina; Sara Monti; Tiziana Vaisitti; Francesca Arruga; Rosella Famà; Carmela Ciardullo; Mariangela Greco; Stefania Cresta; Daniela Piranda; Antony Holmes; Giulia Fabbri; Monica Messina; Andrea Rinaldi; Jiguang Wang; Claudio Agostinelli; Pier Paolo Piccaluga; Marco Lucioni; Fabrizio Tabbò; Roberto Serra; Silvia Franceschetti; Clara Deambrogi; Giulia Daniele; Valter Gattei; Roberto Marasca; Fabio Facchetti; Luca Arcaini; Giorgio Inghirami; Francesco Bertoni; Stefano A Pileri; Silvia Deaglio; Robin Foà; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Gianluca Gaidano
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

10.  The truncate mutation of Notch2 enhances cell proliferation through activating the NF-κB signal pathway in the diffuse large B-cell lymphomas.

Authors:  Xinxia Zhang; Yaoyao Shi; Yuanyuan Weng; Qian Lai; Taobo Luo; Jing Zhao; Guoping Ren; Wande Li; Hongyang Pan; Yuehai Ke; Wei Zhang; Qiang He; Qingqing Wang; Ren Zhou
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240
View more
  8 in total

1.  Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.

Authors:  Vignesh Shanmugam; Jeffrey W Craig; Laura K Hilton; Matthew H Nguyen; Christopher K Rushton; Kian Fahimdanesh; Scott Lovitch; Ben Ferland; David W Scott; Jon C Aster
Journal:  Blood Adv       Date:  2021-01-12

2.  Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.

Authors:  Carolina Jaramillo Oquendo; Helen Parker; David Oscier; Sarah Ennis; Jane Gibson; Jonathan C Strefford
Journal:  Sci Rep       Date:  2019-07-18       Impact factor: 4.379

3.  Human marginal zone B cell development from early T2 progenitors.

Authors:  Mats Bemark; Jo Spencer; Thomas J Tull; Michael J Pitcher; William Guesdon; Jacqueline H Y Siu; Cristina Lebrero-Fernández; Yuan Zhao; Nedyalko Petrov; Susanne Heck; Richard Ellis; Pawan Dhami; Ulrich D Kadolsky; Michelle Kleeman; Yogesh Kamra; David J Fear; Susan John; Wayel Jassem; Richard W Groves; Jeremy D Sanderson; Michael G Robson; David P D'Cruz
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

Review 4.  How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.

Authors:  José Cabeçadas; Victor E Nava; Joao L Ascensao; Maria Gomes da Silva
Journal:  Curr Oncol       Date:  2021-11-11       Impact factor: 3.677

5.  What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts.

Authors:  Côme Bommier; Jérôme Lambert; Grzegorz Nowakowski; Emanuele Zucca; Catherine Thieblemont
Journal:  Hemasphere       Date:  2022-01-31

Review 6.  The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma.

Authors:  David Oscier; Kostas Stamatopoulos; Amatta Mirandari; Jonathan Strefford
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

7.  Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.

Authors:  Thomas Menter; Alexandar Tzankov; Visar Vela; Darius Juskevicius; Stefan Dirnhofer
Journal:  Virchows Arch       Date:  2021-09-08       Impact factor: 4.064

8.  Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.

Authors:  Kazuya Ishiguro; Yasushi Sasaki; Yoshitake Takagi; Takeshi Niinuma; Hiromu Suzuki; Takashi Tokino; Toshiaki Hayashi; Tohru Takahashi; Tetsuyuki Igarashi; Yoshihiro Matsuno
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.